Literature DB >> 15579036

Natural history of the Nihon rat model of BHD.

Kazuo Okimoto1, Mami Kouchi, Izumi Matsumoto, Junko Sakurai, Toshiyuki Kobayashi, Okio Hino.   

Abstract

Hereditary cancer was first described in the rat by Eker and Mossige in 1954 in Oslo. The Eker rat model of hereditary renal carcinoma (RC) was the first example of a Mendelian dominantly inherited predisposition to a specific cancer in an experimental animal, and has been contributing to the elucidation of renal carcinogenesis. Recently, we found a second hereditary RC model in the Sprague-Dawley (SD) rat, in Japan in 2000, which was named the Nihon rat. The Nihon rat is also an example of a Mendelian dominantly inherited predisposition for development of RCs like the Eker rat, which are predominantly of the clear cell type (this type represents approximately 75 % of human RCC), and develop from earlier preneoplastic lesions than the Eker rat. We performed a genetic linkage analysis of the Nihon rat using 113 backcross animals, and found that the Nihon mutation was tightly linked to genes, which are located on the distal part of rat chromosome 10. Finally, we identified a germline mutation in the Birt-Hogg-Dubé gene (Bhd) (rat chromosome 10, human chromosome 17p11.2) caused by the insertion of a single nucleotide in the Nihon rat gene sequence, resulting in a frame shift and producing a stop codon 26 amino acids downstream. Thus, the Nihon rat will contribute to understanding the BHD gene function and renal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579036     DOI: 10.2174/1566524043359737

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  7 in total

1.  Loss of heterozygosity at the FLCN locus in early renal cystic lesions in dogs with renal cystadenocarcinoma and nodular dermatofibrosis.

Authors:  Tina B Bønsdorff; Johan H Jansen; Ragnar F Thomassen; Frode Lingaas
Journal:  Mamm Genome       Date:  2009-04-23       Impact factor: 2.957

2.  The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development.

Authors:  Masaya Baba; Jonathan R Keller; Hong-Wei Sun; Wolfgang Resch; Stefan Kuchen; Hyung Chan Suh; Hisashi Hasumi; Yukiko Hasumi; Kyong-Rim Kieffer-Kwon; Carme Gallego Gonzalez; Robert M Hughes; Mara E Klein; Hyoungbin F Oh; Paul Bible; Eileen Southon; Lino Tessarollo; Laura S Schmidt; W Marston Linehan; Rafael Casellas
Journal:  Blood       Date:  2012-06-18       Impact factor: 22.113

3.  The role of the Birt-Hogg-Dubé protein in mTOR activation and renal tumorigenesis.

Authors:  T R Hartman; E Nicolas; A Klein-Szanto; T Al-Saleem; T P Cash; M C Simon; E P Henske
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

4.  Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin.

Authors:  Andrew R Tee; Arnim Pause
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

Review 5.  Implication of microsatellite instability in human gastric cancers.

Authors:  Upasana Shokal; Prakash C Sharma
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

6.  Haploinsufficiency of the folliculin gene leads to impaired functions of lung fibroblasts in patients with Birt-Hogg-Dubé syndrome.

Authors:  Yoshito Hoshika; Fumiyuki Takahashi; Shinsaku Togo; Muneaki Hashimoto; Takeshi Nara; Toshiyuki Kobayashi; Fariz Nurwidya; Hideyuki Kataoka; Masatoshi Kurihara; Etsuko Kobayashi; Hiroki Ebana; Mika Kikkawa; Katsutoshi Ando; Koichi Nishino; Okio Hino; Kazuhisa Takahashi; Kuniaki Seyama
Journal:  Physiol Rep       Date:  2016-11-15

7.  Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia.

Authors:  Jindong Chen; Kunihiko Futami; David Petillo; Jun Peng; Pengfei Wang; Jared Knol; Yan Li; Sok-Kean Khoo; Dan Huang; Chao-Nan Qian; Ping Zhao; Karl Dykema; Karl Dykyma; Racheal Zhang; Brian Cao; Ximing J Yang; Kyle Furge; Bart O Williams; Bin Tean Teh
Journal:  PLoS One       Date:  2008-10-30       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.